Atormac
brintellex
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 772  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  » Next article
  » Previous article 
  » Table of Contents
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (90 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  


  In this Article
 »  Abstract
 »  Introduction
 »  Material and Methods
 »  Results
 »  Discussion
 »  References

 Article Access Statistics
    Viewed10478    
    Printed308    
    Emailed21    
    PDF Downloaded403    
    Comments [Add]    
    Cited by others 11    

Recommend this journal

   
SHORT REPORTS
Year : 2003  |  Volume : 51  |  Issue : 3  |  Page : 421-422

Intravenous sodium valproate in status epilepticus


Department of Neurology, Sanjay Gandhi PGIMS, Lucknow

Correspondence Address:
Neurology Department, SGPGI, Lucknow
[email protected]

  »  Abstract

A study was conducted to observe the effect of intravenous sodium valproate in status epilepticus. Eleven patients with status epilepticus, who were resistant to conventional drugs, underwent treatment with intravenous sodium valproate. The seizures were controlled in 10 patients within 24-48 hrs of starting treatment. No complications were observed during therapy. We conclude that intravenous sodium valproate can be recommended for Myoclonic status epilepticus and non-convulsive status epileticus.

How to cite this article:
Jha S, Jose M, Patel R. Intravenous sodium valproate in status epilepticus . Neurol India 2003;51:421-2


How to cite this URL:
Jha S, Jose M, Patel R. Intravenous sodium valproate in status epilepticus . Neurol India [serial online] 2003 [cited 2020 Dec 2];51:421-2. Available from: https://www.neurologyindia.com/text.asp?2003/51/3/421/1197


   »   Introduction Top

A variety of drugs have been used for the treatment of status epilepticus (SE). Recently, intravenous sodium valproate has been demonstrated to be effective and safe in the treatment of SE.[1],[2] We report our experience with 11 patients of SE who were resistant to conventional drugs and were treated with intravenous sodium valproate.

   »   Material and Methods Top

The details of the patients are summarized in [Table - 1]. All the patients were managed as per conventional guidelines for SE. The dose of LZ administered was 0.1 mg /kg IV at 2 mg/min. If the seizures persisted after 5-10 min, phenytoin was introduced in a dose of 20 mg /kg at 50 mg/min. If SE persisted for another 15-20 min, the drug was re-administered at a lower dose of 5-10 mg/kg. Intravenous sodium valproate was infused after failure of the above regimen in a dose of 20 mg/kg at 20 mg/min. The drug was repeated whenever required.

   »   Results Top

There were 5 patients of EPC, 4 of MSE and one patient each of NCSE and GTC. Ten patients showed clinical improvement and seizures were controlled within 12-36 hours without any adverse effects. There was no respiratory depression, cardiac arrhythmia or hypotension. These patients remained seizure-free and were then strated on oral anticonvulsant drugs. The efficacy of the treatment did not depend on the type of seizure. There was 1 patient of MSE who did not respond to intravenous sodium valproate alone and required an additional infusion of DZ for control of seizures.

   »   Discussion Top

SE is a life-threatening condition. Oral sodium valproate has established itself as a major antiepileptic drug having efficacy for treatment of both generalized and partial seizures. The role of intravenous sodium valproate in the management of SE is not well established, although controlled trials have shown encouraging results.[3]

Antiepileptic drug-induced hypotension is a well-recognized complication during the management of SE. It has been observed and reported by us that intravenous sodium valproate does not adversely affect the blood pressure.[1] The FDA currently recommends intravenous sodium valproate infusion at the rate of 20 mg/ min. Recent studies have reported tolerability of 50 mg /min infusion in adults with acute seizures and 3-6 mg/ kg/ min infusion in patients with epilepsy.[1]
A high success rate of intravenous sodium valproate has been observed in other studies.[4],[5] This may be due to the rapid penetration of the drug into the brain tissue.[6] We conclude that intravenous sodium valproate can be considered as the first line therapy for EPC. It is also effective and safe in NCSE and Myoclonic status epilepticus.[7]
 

  »   References Top

1.Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients of status epilepticus. Neurology 2000;55:722-4.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Yamamoto LG, Yim GK. The role of intravenous valproic acid in status epilepticus. Pediatr Emerg Care 2000;16:296-8.  Back to cited text no. 2  [PUBMED]  
3.Sheth RD, Gidal BE. Intravenous valproic acid for myoclonic status epilepticus. Neurology 2000;54:1201.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Adin J, Arteaga R, Herranz JL, Armijo JA. The use of intravenous valproate. Rev Neurol 1999;29:744-53.  Back to cited text no. 4  [PUBMED]  
5.Czapinski P, Terczynski A, Intravenous valproic acid administration in status epilepticus. Neurol Neurochir Pol 1998;32:11-22.  Back to cited text no. 5    
6.Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998;338:970-6.   Back to cited text no. 6  [PUBMED]  [FULLTEXT]
7.Honack D, Loscher W. Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res 1992;13:215-21.  Back to cited text no. 7  [PUBMED]  

 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow